Evidence map›Paper›PMID 37965340›Full record

ReviewFrontiers in immunology2023

Langerhans cell histiocytosis: current advances in molecular pathogenesis.

Tommaso Sconocchia, Johannes Foßelteder, Giuseppe Sconocchia, Andreas Reinisch

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Tommaso SconocchiaDivision of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Johannes FoßeltederDivision of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Giuseppe Sconocchia *Institute of Translational Pharmacology, National Research Council (CNR), Rome, Italy.
Andreas Reinisch *Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Medical University of Graz · ATIstituto di Farmacologia Traslazionale · IT

Funding

Austrian Science Fund FWF I 5021Austrian Science Fund FWF P 32783
6 · The paper itself

Abstract

Langerhans cell histiocytosis (LCH) is a rare and clinically heterogeneous hematological disease characterized by the accumulation of mononuclear phagocytes in various tissues and organs. LCH is often characterized by activating mutations of the mitogen-activated protein kinase (MAPK) pathway with

Indexed as

Histiocytosis, Langerhans-CellProto-Oncogene Proteins B-rafGain of Function MutationHumansMitogen-Activated Protein KinasesMutationMitogen-Activated Protein KinasesProto-Oncogene Proteins B-rafBRAFV600Edendritic cellslangerhans cell histiocytosisMAP2K1monocytesoncogenesenescence

Identifiers

PMID37965340
PMCPMC10642229
OpenAlexW4388201551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.